Purpose To describe cases of optic pathway glioma (OPG) warranting treatment in children. Methods This is a retrospective review of pediatric patients treated for OPG. The clinical data and imaging studies were obtained from the medical records and radiology files of patients seen at the Pediatric NeuroOphthalmology Clinic at the University of Illinois, Chicago and the private office of the author (LMK). Results A total of seven cases with an age range of 3-48 months at presentation were reviewed. Three of the patients were also ultimately diagnosed with neurofibromatosis type 1. Presenting symptoms included proptosis, decreased vision, gaze deficit, and nystagmus. Four patients underwent biopsies that confirmed OPG. Six of the patients were treated with intravenous chemotherapy, with three patients requiring a second chemotherapy cycle. One patient was successfully treated with an en-bloc optic nerve excision. Two patients underwent unilateral enucleation owing to globe complications. Conclusion Although benign tumours, OPG can behave very aggressively in young children. Both chemotherapy and en-bloc excision can be employed for treatment.
Introduction
Optic pathway glioma (OPG) is a low-grade astrocytic tumour that can involve the visual pathways from the optic nerves to the visual cortex. These tumours account for 4-8% of all brain tumours in children. 1 In approximately 50% of these patients, OPG occurs in isolation; the other 50% of these patients have neurofibromatosis type 1 (NF1). 2 There is a 15-20% incidence of OPG in patients with NF1. 3, 4 The clinical presentation of OPG is quite variable depending on the tumour location and extent. [4] [5] [6] [7] Many patients are asymptomatic. 4, 5 Patients with tumours within the orbit present with proptosis, strabismus, and/or visual loss.
Intracranial OPG can present with visual and endocrine impairment. Papilledema or optic atrophy may be evident. Once OPG is diagnosed, most cases show a very indolent growth or are non-progressive, with little or no change in the clinical status. 4, 5 As an example; Figure 1 shows a representative MRI cut from a patient the author (LMK) has followed for 8 years. This patient's clinical findings and imaging results have remained unchanged during this whole period of observation. Spontaneous regression of OPG has also been reported. 8, 9 In a minority of the cases of OPG, the tumour shows aggressive local expansion, leading to progressive deterioration in vision. 6 It is not known why some tumours grow aggressively whereas others remain static. OPG in NF1 has been reported to behave less aggressively than OPG in isolation. 2 Younger age at presentation is also a risk factor for growth. 10 Treatment for progressive OPG is available with chemotherapy, radiotherapy, or surgery. Multiple studies have been reported on the advantage of chemotherapy for OPG in young children, but no widely accepted protocol yet exists. [11] [12] [13] Each patient with OPG requires a team approach, with individualized treatment.
In this article, we present a case series of seven young children with aggressive OPG threatening vision and warranting treatment to arrest tumour progression and salvage remaining vision.
Materials and methods
At the Pediatric Neuro-Ophthalmology clinic at the University of Illinois at Chicago and the private pediatric ophthalmology practice of the author (LMK), a search of charts was performed to identify pediatric patients treated for OPG. Seven patients were identified, and all are included in this report. Patients with OPG that did not require treatment are excluded from this study. Clinical information was obtained from the patients' medical files and medical imaging files. The information collected included general demographic data, symptoms and signs at the time of presentation, eye findings noted during serial ophthalmologic examinations, the results from serial medical imaging studies, biopsy results, NF1 work-up results (determined by referral to a pediatric Geneticist), and the treatment regimens. A more detailed clinical report, with items such as visual field, colour vision, and exophthalmometry could not be obtained in most cases because of the very young ages of the patients. Medical imaging was performed with computed tomography (CT) and/or MRI, in most cases every 6 months after diagnosis.
Criteria for the recommendation to treat (and re-treat) the OPGs included documented progression of the tumour or extensive involvement at the time of presentation. The decision to suggest treatment represented a consensus of opinion of the medical team that included a pediatric ophthalmologist, pediatric neurologist, and pediatric oncologist.
An Institutional Review Board/Ethics Committee approved this study, and the work is HIPAA-compliant.
Results
Patients' ages ranged from 3 to 48 months (average 22 months) at the time of presentation for medical evaluation. Four girls and three boys are included. Follow-up was available for all patients, and ranged from 40 months to 13 years (average 67 months). Table 1 presents the demographic information, chief complaint, eye findings, and medical imaging results of all the patients at the time of their presentation for medical care. In four of the patients, the diagnosis of OPG was confirmed by biopsy (Table 1 ). In the remaining three, the index of suspicion was high enough based on the clinical setting to warrant treatment for OPG despite a lack of tissue confirmation. Three of the patients were ultimately diagnosed with NF1 (Table 1) . Clinical photographs and serial medical imaging studies of the patients are presented in Figures 2-8 .
Five of the seven patients presented with progressive proptosis evident over a time ranging from 6 weeks to 6 months. Patient No. 3 was thought by her local pediatrician to have signs of precocious puberty, prompting a brain MRI that revealed an extensive OPG. Figure 1 Brain MR images from a patient with neurofibromatosis type 1. At the age of 9 years his first brain MRI was obtained (ordered to work-up attention deficit disorder), and revealed glioma involving posterior intraorbital optic nerve on the right, bilateral intracanalicular and intracranial optic nerves, and chiasm. Serial MRI's performed on a yearly basis over the ensuing 8 years revealed no change in the extent of the glioma. Serial eye exams during this time period also revealed stable findings; visual acuity 20/70 þ OD and 20/60À OS, Lisch nodules, and symmetric temporal optic pallor OU. The patient received no treatment for the glioma. (a, b) T1-weighted post-contrast axial brain MR images obtained when the patient was 9 years old. (a) Image shows glioma involving the right intraorbital optic nerve (long arrow), and bilateral intracanalicular and intracranial optic nerves (short arrows). (b) Chiasm is diffusely enlarged due to glioma (asterisk).
Subsequent evaluation of patient #3 by a universitybased pediatric endocrinologist ruled-out precocious puberty; thus, the discovery of her OPG was serendipitous.
Loss of vision at presentation was profound (poor fixation, afixational, or light perception) in six eyes of five patients. Only patient #3 seemed to have bilateral, relatively preserved vision at the time of presentation.
Treatment for patients #1, 2, and 4-5, and 6 was recommended because of a history of progressive proptosis, and medical imaging showing extensive disease (Figures 2, 3 , and 5-7). Patients #3 and 7 were offered treatment based on the extent of involvement documented by their initial brain MRI (Figures 4 and 8) , and also for patient # 7 because of the profound loss of vision and sensory nystagmus apparent at her presentation.
For the initial treatment of the OPG, five of the patients (#2, 3, and 5-7) were enrolled in the Children's Oncology Group Chemotherapy Protocol A9952 (Chemotherapy for progressive low grade astrocytoma in children less than 10 years old). As per the protocol, the children without NF1 (patients #3, 5, 7) were randomized into one of two different chemotherapy regimens, Regimen A and Regimen B. Regimen A consisted of carboplatin i.v. and vincristine i.v. for 60 weeks. Regimen B consisted of thioguanine p.o., procarbazine p.o., lomustine p.o., and vincristine i.v. for 52 weeks. Also, as per the protocol, the children with NF1 (patients #2, 6) were nonrandomly assigned to Regimen A, so as to avoid the alkylating agents procarbazine and lomustine (known to cause leukaemia in susceptible patients, ie, patients with NF1).
Patient #1 presented at 3 months of age with progressive proptosis of the right eye noted since birth. See Table 1 for the initial clinical findings. The MRI showed an OPG involving both optic nerves and the chiasm, with marked volume expansion of the optic nerve on the right (Figure 2a-c) . Treatment for the OPG with chemotherapy as per the protocol was immediately recommended, but deferred 1 month as the patient's family sought a second opinion. At 4 months of age, the patient started chemotherapy off the protocol with carboplatin i.v. and vincristine i.v. for 72 weeks. Between 3 and 5 months of age, there was a marked increase in his right eye proptosis resulting in exposure keratopathy, and ultimately, a corneal perforation. The right eye was deemed unsalvageable, and enucleated. At the same time, an incisional biopsy of the optic nerve mass was obtained, and revealed juvenile pilocytic astrocytoma.
Patient #4 presented at 39 months of age with a 6-week history of progressive proptosis and limited upgaze of the left eye ( Table 1 ). The CT scan revealed a large optic nerve mass confined to the left orbit (Figure 5a ). He was then observed for one month; vision, proptosis, and papilledema ( Figure 5b ) were seen to markedly worsen. As the mass seemed contained within the orbit, it was elected to treat with an en-bloc excisional biopsy of the intraorbital optic nerve (Figure 5c ). The globe was left in situ. The pathological specimen was interpreted as juvenile pilocytic astrocytoma. Four months after the surgery, the patient's left eye developed a tractional retinal detachment (Figure 5d ), ultimately leading to phthisis. The left eye was enucleated when the patient was 15 years old.
Outcome Patients #1-3 have shown a long-term arrest of their OPG in response to the treatment of their tumours with one course of chemotherapy. These tumours' favourable responses, as noted in post-treatment serial MRIs, appear as a modest shrinkage in the tumour volumes and less enhancement with contrast. In no cases did the MRI appearance of the OPG substantially 'melt away' in response to the chemotherapy. For patient #4, the tumour excision has appeared curative. The treatment and long-term outcome for the four patients responsive to single treatment are presented in Table 2 . For this group, follow-up ranged from 40 months to 13 years. Comparisons of initial to final vision and proptosis are difficult to make in this group because of the young age at presentation and the enucleation of two of the eyes. In general, the vision loss sustained by these patients seems not to have progressed after initiation of treatment (compare visions in Tables 1 and 2 ). Side-by-side comparisons of patients' #1-3 initial and final MRIs are shown in Figures 2-4 .
After the completion of their initial course of chemotherapy, patients #5-7 showed further progression of their OPG as determined by serial MRIs. Considering the patients' ages, the results from their serial eye examinations did not seem sensitive or accurate enough to document clinical deterioration. The initial treatment of these patients and their clinical and MRI findings at the time of tumour progression are detailed in Table 3 . Tumour progression was noted 29, 5, and 44 months after completion of their initial course of chemotherapy for patients #5-7, respectively. All three of these patients ultimately received a second course of chemotherapy (Table 3) .
For patients #6 and 7, the second course of chemotherapy was started within the same month that tumour progression was documented by MRI. Patient #5 started her second chemotherapy course 16 months after progression was noted, a delay in consideration of a surgical resection of the tumour. The second chemotherapy regimens for these patients are shown in Table 3 .
Final MRIs were available for patients #6 and 7, 23 and 30 months, respectively, after completion of their second course of chemotherapy (Figures 7 and 8) . For both these patients, the tumour showed no further growth since the start of their second course of chemotherapy (Table 4) . Patient #5 had just started her second course of chemotherapy at the time of this writing. Serial MRIs of patient #5, from the time progression of the OPG was first noticed at 56 months of age to the most recent scan at 68 months, show slow but continuous growth of the OPG.
The eye findings of patients #5-7 at their final examination are shown in Table 4 . Considerable loss of vision was evident in four out of six eyes, similar to the findings at the initial presentations.
Discussion
Herein are described seven young patients with OPG causing a variety of visual system symptoms and signs: proptosis, decreased visual acuity, strabismus, nystagmus, optic atrophy, and papilledema. Treatment was recommended for all the patients, and in three cases the tumour progressed even after an initial course of chemotherapy.
Our report demonstrates that OPG can behave aggressively with local expansion resulting in progressive clinical findings. Treatment of our patients was deemed advisable to arrest further damage to the visual system. Although the majority of patients with OPG have an indolent or asymptomatic course, numerous studies have documented symptomatic progression of OPGs such that treatment was necessary to preserve vision or life. 14 22 The product of the NF1 gene is a protein termed neurofibromin.
23 NF1 patients are born with one intact NF1 allele and one dysfunctional allele from a germline mutation. Later dysfunction of the previously intact NF1 allele in a somatic cell results in a complete loss of neurofibromin in that cell. If this 'second hit' occurs in a vulnerable cell during an age of vulnerability, the cell loses mitotic control and develops into a tumour line. 24 This complete loss of NF1 gene expression has been demonstrated in all NF1-associated tumours, including OPG. 25 In these vulnerable cells, neurofibromin acts as a tumour suppressor. 26 Neurofibromin is a guanosine triphosphataseactivating protein for Ras (an important component of the signal transduction pathway used by growth factors to initiate cell growth and differentiation), and has been proposed to regulate cell growth by inhibiting Ras activity. 23 In the absence of neurofibromin, Ras activity is unabated. Neurofibromin may also play a role in regulating other tumour suppressor genes such as TSC2, and other growth pathways such as mTOR. 27 The role of neurofibromin in the genesis of OPG is limited to patients with NF1. In the cells of sporadic OPG (ie, not associated with NF1), the expression of the NF1 gene and neurofibromin levels are normal, thus implicating an alternate pathway to OPG formation. 28, 29 Another cellular factor that may play a role in OPG growth is DNA topoisomerase IIalpha, an essential nuclear enzyme required for chromatin condensation and chromosome segregation during mitosis. Expression of DNA topoisomerase IIalpha has been shown to correlate with tumour cell proliferation in pediatric OPGs. 30 At the macroscopic level, growth of OPG has been reported to be associated with sporadic, non-NF1 cases and younger age at presentation.
2,10 All of our patients were 4 years of age or younger at presentation, and four out of seven had sporadic OPG. In a series reported by Singhal et al 16 , 11 out of 17 NF1-associated OPG patients and 14 out of 17 sporadic OPG patients received treatment for progressive OPG disease. These authors also noted that the average age at diagnosis of all their OPG patients (treated and untreated) was 5.0 and 5.8 years of age for the NF1 and sporadic OPG patients, respectively. In Astrup's 15 series, four out of 12 NF1-associated OPG patients and nine out of 13 sporadic OPG patients were treated for progressive disease. The mean age at diagnosis for the NF1 OPG patients was 3 years, and 6 years for patients with sporadic OPG. Khafaga et al 17 identified OPG-treated patients at a national cancer referral centre, and noted that 32 out of 50 patients had sporadic OPG vs 18 out of 50 with NF1-associated OPG. The mean age of all the patients in Khafaga's series was 4 years at the time of diagnosis. Listernick et al 2 reported on 36 patients with OPG. They found no significant difference between the children with NF1-associated OPG and those with sporadic OPG as to age at diagnosis or sex distribution. Progressive disease was seen in 12% of patients with NF1 OPG as compared to 63% of those with sporadic OPG.
In actuality, the association of OPG growth with sporadic, non-NF1 cases may be factitious, as selection bias can be identified in these aformentioned studies. Because of the known association of NF1 with OPG, many asymptomatic patients with NF1 undergo medical imaging of the brain for screening purposes. 4 (At the authors' institution, only symptomatic patients undergo imaging.) This type of screening of NF1 patients will result in the identification of patients with mild, asymptomatic, and/or indolent OPGs that do not require treatment. In contrast, with sporadic OPG, only patients with symptomatic disease undergo brain imaging. Asymptomatic patients with sporadic OPG are identified only by serendipity; the prevalence of asymptomatic sporadic OPG in the general population can only be known with massive screening initiatives. Thus, most reports comparing the aggressiveness of NF1-associcated OPG vs sporadic OPG will be biased towards mild disease in NF1 patients, and towards advanced disease in non-NF1 patients.
In a natural history study reported by Listernick et al, 4 patients with NF1-associated OPG were collected prospectively from a neurofibromatosis clinic. Of 227 children with NF1 seen in the clinic, 176 (77%) underwent neuroimaging, including many asymptomatic patients. Thirty-three children (19%) were found to have OPG; 'Although eight tumours were discovered because of ophthalmologic complaints or evidence of precocious puberty, 25 children (76%) were free of symptoms at the time of diagnosis. Twenty-one children (64%) had normal ophthalmologic findings at diagnosis; six children, all with chiasmal tumours, had previously unrecognized decreased visual acuity. Only three children (9%) had evidence of either tumour growth or deteriorating vision after diagnosis'. Thus, this type of series of patients with NF1-associated OPG is strongly biased towards mild OPG disease. Czyzyk et al 31 reported on 83 children with OPG: 34 out of 51 (66.7%) children with NF1-associated OPG and 29 out of 32 (90.6%) children with sporadic OPG had received treatment for progressive disease. However, this apparent significant difference in treatment rates is tainted by selection bias: the NF1 patients were collected from the 'Department of Pediatrics of the Central Hospital and Pediatric Neurology Unit in Rzeszow and the Department of Neurology of the Children's Memorial Health Institute in Warsaw, the sporadic OPG cases were all collected from the Neurological and/or Neurosurgical Department of the Children's Memorial Health Institute in Warsaw'. It is to be expected that the most severe cases of OPG in Poland were referred to their Capital's children's hospital for neurosurgery, thus biasing the sporadic disease numbers towards more advanced disease.
Listernick et al 2 tried to avoid this bias in their comparative study mentioned above. Patients with NF1-associated OPG were recruited from a neurofibromatosis clinic, but only children with symptomatic NF1-associated OPG were included in the study for comparison to patients with sporadic OPG. Progressive disease was seen in 12% of patients with symptomatic NF1-associated OPG as compared to 63% of those with sporadic OPG. Even though this difference in progression rates seems compelling, the NF1 OPG patients were still drawn from a screened, high-risk population where equivocal or mild symptoms would be investigated, thus biasing the NF1 OPG patients towards mild disease. Despite the inherent bias in reports comparing NF1-associated OPG and sporadic OPG, the age at presentation in these two groups appears very similar in the aformentioned studies. In the report by Czyzyk et al, 31 all of the OPGs were found in children below 10 years of age, only slightly earlier in the sporadic group (median age 4.6 vs 4.8 years). None of these aforementioned studies broke down their data to show age at diagnosis of patients who required treatment vs patients who did not receive treatment. Thus, the data do not convincingly support the notion that progressive OPG disease is associated with younger age at presentation.
Treatment
For those patients with progressive OPG, treatment is available with chemotherapy, radiation therapy, and/or surgery. Five out of the seven patients reported here received their initial chemotherapy based on our institution's pediatric oncologist's participation in the Children's Oncology Group Chemotherapy Protocol A9952. This Protocol is now nearing its completion (enrolment closed on 31 January 2005), and the initial results should soon be available. Data showing the effectiveness of chemotherapy in the treatment of progressive low-grade glioma have been accumulating over the past 25 years. Carboplatin, cisplatin, vincristine, vinblastine, actinomycin D, lomustine, thioguanine, procarbazine, dibromodulcitol, etoposide, tamoxifen, and temozolomide, alone or in combination, as primary treatment or as adjuvant, have all been utilized. [10] [11] [12] [13] 19, [32] [33] [34] [35] [36] [37] [38] [39] [40] Although chemotherapy has emerged as promising therapy, no regimen has yet to be universally accepted, hence the current Children's Oncology Group trial.
Treatment of low-grade glioma by surgical resection is also available. 15, 17 Glioma tumour cells diffusely infiltrate brain tissue, and so, in most cases the resections are subtotal. During surgical excision of OPG, visual pathway fibres must be sacrificed, resulting in a corresponding loss of vision. Thus, surgery for OPG is usually limited to cases with (1) disease confined to the intraorbital portion of the optic nerve, and (2) ipsilateral, unilateral blindness. Our patient #4 fit these criteria, and was treated accordingly, and has shown a long-term eradication of his OPG.
Treating children younger than 5 years of age with radiotherapy to the brain carries serious side effects involving intellect and the endocrine system, thus limiting its usefulness in the treatment of OPG in early childhood. 41 Newer modalities of delivering radiotherapy, such as stereotactic radiotherapy and the Gamma Knife, may lessen side effects and preserve effectiveness. 42, 43 Three of our patients continued to show tumour progression after their first course of chemotherapy, and received a second, non-protocol course of chemotherapy that was individualized to each patient. Similarly, failure of initial treatment of progressive OPG has been observed by others. Khafaga et al 17 noted that 14 (31%) of 45 patients who received treatment for OPG had tumour progression after treatment with surgery and/or radiation. Treatment failure seemed related to tumour site: 78% of their failures were in posterior tumours, and no failures were seen in patients with disease limited to the optic nerve. Posteriorly located OPGs also tend to cause more vision loss than anteriorly located tumours. 5 Overall, a more favourable outcome with OPGs is seen in patients older than 2 years of age, with NF1, and with optic nerve and/or chiasmatic lesions. 2, 6, 10, 13 Determining the best treatment for your next patient with progressive OPG is not currently defined in the medical literature. Comparing the success rates of the various treatment modalities, across the multiple publications on the subject, is fraught with pitfalls: many of the studies are retrospective, inclusion, and exclusion criteria are lacking, treatments are not standardized or randomized, and outcomes are not clearly stated. Large, prospective, well-controlled studies such as the Children's Oncology Group Chemotherapy Protocol A9952 are required to make outcome-based comparisons as to the effectiveness of different treatments.
Effective management of patients with OPG must involve a team approach, and depending on the circumstances, with input from ophthalmology, neuroradiology, oncology, neurosurgery, and/or radiation oncology. As patients with OPGs are most likely young children at the time of diagnosis, physicians with pediatric subspecialty training are advisable. Documented progression, as occurs in the minority of OPG patients, warrants treatment to preserve vision and life. In the authors' experience, the decision to treat relies both on the ophthalmology findings and medical imaging results, although the ophthalmologist's role may be limited in some of these patients considering the unreliability of the ocular measurements in children. The aggressive nature of the tumours as seen in this study, even after initial treatment, stresses the importance of frequent follow-up with ocular and medical imaging examinations.
